BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease
08 sept. 2023 08h30 HE
|
BioRestorative Therapies, Inc
--Site activation allows for patients in the State of New York to participate in the BRTX-100 trial— --15 Clinical Sites Identified, 12 of the 15 Activated and Recruiting Subjects MELVILLE,...
BioRestorative Therapies Announces $2.1 Million Registered Direct Offering
11 juil. 2023 08h30 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., July 11, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based...
BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes
27 juin 2023 07h00 HE
|
BioRestorative Therapies, Inc
No Dose Limiting Toxicity (DLT) was Observed in the Patients in the Safety Run-In Segment of StudyDSMB Recommendation Allows for Open Enrollment MELVILLE, N.Y., June 27, 2023 (GLOBE NEWSWIRE) --...
BioRestorative Therapies, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
16 juin 2023 07h00 HE
|
BioRestorative Therapies, Inc
MELVILLE, NY., June 16, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease
12 juin 2023 07h00 HE
|
BioRestorative Therapies, Inc
--Clinical data expected to be reviewed by independent data safety monitoring board (DSMB) as to initial safety dosing profile of BRTX-100-- MELVILLE, N.Y., June 12, 2023 (GLOBE NEWSWIRE) --...
BioRestorative Therapies, Inc. to attend the Jefferies 2023 Healthcare Conference
01 juin 2023 09h15 HE
|
BioRestorative Therapies, Inc
MELVILLE, NY., June 01, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Receives License from New York State Department of Health to act as Tissue Bank for Mesenchymal Stem Cell Processing
31 mai 2023 07h00 HE
|
BioRestorative Therapies, Inc
--License will enable expanded clinical operations for investigator-initiated trials and potential “right to try” uses of BRTX-100.— MELVILLE, N.Y., May 31, 2023 (GLOBE NEWSWIRE) --...
BioRestorative Therapies Receives Notice of Allowance by the Japanese Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program
15 mai 2023 07h00 HE
|
BioRestorative Therapies, Inc
--Upon issuance, patent will be the fourth Japanese patent to issue for the ThermoStem® program targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., May 15, 2023 ...
BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Company’s Phase 2 Clinical Trial
08 mai 2023 07h00 HE
|
BioRestorative Therapies, Inc
New York State’s largest health care provider will participate in BRTX’s clinical trial Expansive universe of patients and clinical sites from which to recruit high quality subjectsLeverage...
BioRestorative Therapies, Inc. to participate at the EF Hutton Global Conference May 10-11 in New York City
04 mai 2023 07h00 HE
|
BioRestorative Therapies, Inc
MELVILLE, NY., May 04, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...